Business Context and Reporting Period
Company: Indivior PLC (INDV)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Indivior is a global pharmaceutical company focused on treating substance use disorders (SUDs), primarily opioid use disorder (OUD). Its core portfolio includes SUBLOCADE (long-acting injectable), SUBOXONE (sublingual film/tablets), and OPVEE (opioid overdose reversal). The U.S. market accounted for 85% of net revenues in 2024. The company transitioned its primary stock listing from the London Stock Exchange to Nasdaq in June 2024 and adopted U.S. GAAP for financial reporting.
Key Financial Metrics
| Metric (in millions, except per share) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Revenue | $1,188 | $1,093 | $901 |
| Operating Income (Loss) | $32 | $(156) | $(81) |
| Net Income (Loss) | $2 | $(129) | $(44) |
| Diluted EPS | $0.02 | $(0.94) | $(0.32) |
| Gross Margin | 81% | 84% | 83% |
| Operating Cash Flow | $36 | $(300) | $(4) |
| Cash and Investments | $347 | $451 | N/A |
| Total Debt (Long-term + Current) | $333 | $240 | N/A |
Note: 2023 operating cash flow was significantly impacted by $387 million in litigation settlement outflows.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 9% to $1.188 billion, driven primarily by a 20% increase in SUBLOCADE sales ($756 million) and the launch of OPVEE ($15 million). This offset a 10% decline in sublingual products due to generic competition.
- Profitability Turnaround: The company returned to operating profitability ($32 million) compared to a $156 million loss in 2023. This improvement was driven by revenue growth and a significant reduction in litigation settlement expenses ($195 million in 2024 vs. $239 million in 2023).
- Product Discontinuation: In July 2024, the company ceased marketing and promotion of PERSERIS (schizophrenia treatment) due to unfavorable market dynamics, incurring $53 million in restructuring and impairment charges.
- Debt Refinancing: In November 2024, the company refinanced its term loan, replacing the previous facility with a new $350 million term note and a $50 million revolving credit facility, maturing in 2030.
- Share Repurchases: The company completed two share repurchase programs in 2024, canceling approximately 15.4 million shares for a total cost of roughly $202 million.
Guidance, Outlook, and Risks
- 2025 Outlook: Management expects an overall decline in total net revenue and operating income in 2025 compared to 2024. This is attributed to an accelerated decline in SUBOXONE Film revenue due to generic competition (including a potential fifth entrant) and minimal revenue from PERSERIS following the cessation of marketing.
- Manufacturing Expansion: The company is investing $50–$70 million in 2025 to build out its Raleigh, NC manufacturing facility to secure long-term supply of SUBLOCADE, with production expected to begin in late 2026.
- Key Risks:
- Litigation: Significant exposure remains regarding the Opioid MDL (multi-district litigation), with a preliminary settlement provision of $76 million recorded. Dental injury lawsuits related to SUBOXONE Film are ongoing.
- Regulatory Compliance: The company is subject to a Corporate Integrity Agreement (CIA) with HHS-OIG and a Resolution Agreement with the DOJ, requiring strict compliance and reporting until 2027 (with options to extend).
- Competition: SUBLOCADE faces competition from BRIXADI (Camurus/Braeburn). SUBOXONE Film faces intense generic competition, with market share declining to 16% in 2024.
- Liquidity: Current liabilities exceed current assets by over $100 million. Liquidity depends on sustained sales volume and the timing of rebate payments.
Investor Verification Checklist
- Litigation Settlement Terms: Verify the final terms and payment structure of the Opioid MDL settlement, as the current $76 million provision is based on a preliminary agreement.
- Rebate Accruals: Review the $565 million liability for accrued rebates and product returns, which is a critical accounting estimate sensitive to payer mix and utilization trends.
- Debt Covenants: Confirm compliance with the new Note Purchase Agreement covenants, specifically the Total Leverage Ratio (max 3.0:1 through 2026) and Interest Coverage Ratio (min 2.5:1).
- Manufacturing Timeline: Monitor the progress of the Raleigh facility build-out and regulatory approvals, as delays could impact SUBLOCADE supply security and cost savings targets.
- Generic Erosion: Track the market share decline of SUBOXONE Film and the impact of the fifth generic entrant expected in early 2025 on 2025 revenue guidance.